High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation

Bone Marrow Transplantation

Volumn 26, Issue 3, 2000, Pages 251-255

  Mohty, M ^c   Faucher, C ^c   Vey, N ^c   Stoppa, A M ^c   Viret, F ^c   Chabbert, I ^c   Chabannon, C ^c   Bouabdallah, R ^c   Ladaique, P ^c   Collet, L ^c   Zandotti, C ^c   Maraninchi, D ^a   Blaise, D ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c NONE

Author keywords

Allogeneic bone marrow transplantation; Cytomegalovirus; Nonmyeloablative conditioning; Septicemia

Indexed keywords

ACICLOVIR; BUSULFAN; COTRIFAMOLE; CYCLOSPORIN A; FLUDARABINE; FLUDARABINE PHOSPHATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SEPTICEMIA; VIRUS INFECTION;

EID: 0033866719     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702509     Document Type: Article

References (20)

1. Bortin MM, Horowitz MM, Rimm AA. Increasing utilization of allogeneic bone marrow transplantation. Results of the 1988-1990 survey. Ann Intern Med 1992; 116: 505-512.
2. Klingemann HG, Storb R, Fefer A et al. Bone marrow transplantation in patients aged 45 years and older. Blood 1986; 67: 770-776.
3. Blume KG, Forman SJ, Nademanee AP et al. Bone marrow transplantation for hematologic malignancies in patients aged 30 years or older. J Clin Oncol 1986; 4: 1489-1492.
4. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
5. Ben-Yosef R, Or R, Nagler A, Slavin S. Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia (letter). Lancet 1996; 348: 1242-1243.
6. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T cell depletion. Ann Intern Med 1988; 108: 806-814.
7. Gale RP, Horowitz MM, Ash RC et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120: 646-652.
8. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
9. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
10. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
11. Blaise D, Jourdan E, Michallet M et al. Mobilisation of healthy donors with lenograstim and transplantation of HLA-geno-identical blood progenitors in 54 patients with hematological malignancies: a pilot study. Bone Marrow Transplant 1998; 22: 1153-1158.
12. Blaise D, Kuentz M, Fortanier C et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation: a report from the Société Française de Greffe de Moelle. J Clin Oncol 2000; 18: 537-546.
13. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478-488.
14. Boeckh M, Bowden RA, Goodrich JM et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992; 80: 1358-1364.
15. Schmidt GM, Horak DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. The City of Hope-Stanford-Syntex CMV Study Group. New Engl J Med 1991; 324: 1005-1011.
16. Zaia JA, Schmidt GM, Chao NJ et al. Pre-emptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up. Biol Blood Marrow Transplant 1995; 1: 88-93.
17. Bacigalupo A, Tedone E, Isaza A et al. CMV-antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigen positive cell numbers with transplant-related mortality. Bone Marrow Transplant 1995; 16: 155-161.
18. Hertenstein B, Hampl W, Bunjes D et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant 1995; 15: 387-393.
19. Einsele H, Ehninger G, Steidle M et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood 1993; 82: 1672-1678.
20. Wingard JR, Piantadosi S, Burns WH et al. Cytomegalovirus infections in bone marrow transplant recipients given intensive cytoreductive therapy. Rev Infect Dis 1990; 12 (Suppl. 7): S793-S804.